Because older age has been reported as a negative prognostic factor in malignant melanoma patients in the previous studies, therefore, researchers compared younger and older malignant melanoma inpatients, in terms of comorbidities, medical complications, and inpatient mortality.
Publications
Clinical utility of skin cancer and melanoma risk scores for population screening: TRoPICS study
Researchers conducted the study for evaluating the clinical utility of risk?assessment tools to identify people with prevalent skin cancers in a volunteer?based screening clinic.
Indoor tanning exposure in association with multiple primary melanoma
Researchers undertook this retrospective case?control study to examine the link between indoor tanning and the development of multiple primary melanoma.
Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for a Phase 2 clinical trial, LUMINOS-102, to investigate the efficacy and safety of PVSRIPO alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor in patients with treatment-refractory melanoma.